drugset / Trial / NCT03373461
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
RandomizedParallel-groupDouble-blindTreatment
Summary
Efficacy and safety of LNP023 in IgAN patients
Timeline
- Start
- 2018-02-07
- Primary completion
- 2020-12-29
- Completion
- 2021-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iptacopan | Small molecule | 10 mg | — |
| Subject | Iptacopan | Small molecule | 50 mg | — |
| Subject | Iptacopan | Small molecule | 100 mg | — |
| Subject | Iptacopan | Small molecule | 200 mg | — |